Here is another recent item.
HemispheRxunfairly shorted - Business Week
NEW YORK, Nov 12 (Reuters) - HemispheRx BioPharma Inc. (AMEX:HEB - news) and Organogenesis Inc. (AMEX:ORG - news) are being unfairly shorted, says a money manager in the November 23 issue of Business Week.
Organogenesis plummeted from 37 in late April to 12-5/8, while Hemispherx fell from 12-1/2 on September 9 to 5 on September 25.
On November 12, Organogenesis closed at 13-3/4, up 1-3/16, on the American Stock Exchange, and Hemispherx, also on the AMEX, closed at 8-3/16, down 1/8.
Ray Dirks, founder of the ShortBusters Club, said in the article that Hemispherx is within two years of commercializing a new class of drugs for chronic viral disorders. Hemispherx's Ampligen has been called unsafe and defective by short sellers.
''They're wrong,'' says Dirks. ''If the drug was unsafe, the FDA wouldn't have permitted its use in this manner.''
The drug is in Phase III clinical trials, with patients paying the cost of the drugs.
Hemispherx, he says, aims to develop an oral version of Ampligen, called Oragen, as well as other products for treating viral, immune deficiency, and other cancerous conditions.
----------------------------------------------------------------------
|
